<p>Osimertinib is indicated for the treatment of patients with metastatic&nbsp;epidermal growth factor receptor&nbsp;(EGFR) T790M mutation-positive&nbsp;non-small cell lung cancer&nbsp;(NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.</p>